Serum cholesterol and mTOR inhibitors: Surrogate biomarker or epiphenomenon?

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 2999-3001

  Cho, Daniel C ^a   Atkins, Michael B ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHOLESTEROL; EVEROLIMUS; LOW DENSITY LIPOPROTEIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TEMSIROLIMUS;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL SYNTHESIS; DISEASE MARKER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK REDUCTION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHOLESTEROL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; SIROLIMUS;

EID: 84861777925     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0953     Document Type: Article

References (12)

1. Lee CK, Marschner IC, Simes J, Voysey M, Egleston BL, Hudes G, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012;18:3188-96.
2. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A;, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. (Pubitemid 46849157)
3. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U S A 2011;108: 15201-6.
4. Sharpe LJ, Brown AJ. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun 2008;373:670-4.
5. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007;166:932-40. (Pubitemid 47511687)
6. Brock KE, Gridley G, Chiu BC, Ershow AG, Lynch CF, Cantor KP. Dietary fat and risk of renal cell carcinoma in the USA: a case-control study. Br J Nutr 2009;101:1228-38.
7. Gebhard RL, Clayman RV, Prigge WF, Figenshau R, Staley NA, Reesey C, et al. Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 1987;28:1177-84. (Pubitemid 17151580)
8. Drabkin HA, Gemmill RM. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res 2010;107:39-56.
9. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47. (Pubitemid 41103678)
10. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103: 763-73.
11. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47. (Pubitemid 41115390)
12. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18. (Pubitemid 41103603)